Eyal Desheh

Headshot - Desheh, Eyal - Cropped.jpg

Chairman, MigVax

Eyal Desheh is the chairman of the board of MigVax LTD, an Israeli research company which is developing a protein based vaccine for the COVID 19 virus.

A veteran of the Israeli pharma and high tech industries, Eyal served as CFO and head of BD at Check Point Software and Teva Pharmaceuticals where is was also interim CEO.

Eyal served on the board of Mobileye which was sold to Intel in a $15 billion transaction and on the boards of a number of additional companies such a Stratasys LTD and ECI telecom. He is deeply involved with the Israel’s high tech and health care industries and serves on numerous boards of promising startups. He holds B.A in economics and MBA from the Hebrew University in Jerusalem.